{
    "Trade/Device Name(s)": ["AlloMap Heart Molecular Expression Testing", "AlloMap Heart Testing"],
    "Submitter Information": "CareDx, Inc.",
    "510(k) Number": "K221640",
    "Predicate Device Reference 510(k) Number(s)": ["K073482"],
    "Regulatory Class": "Class II",
    "Product Code(s)": ["OJQ"],
    "Summary Letter Date": "",
    "Summary Letter Received Date": "",
    "Submission Date": "April 7, 2023",
    "Regulation Number(s)": ["21 CFR 862.1163"],
    "Regulation Name(s)": ["Cardiac Allograft Gene Expression Profiling Test System"],
    "Analyte Class(es)": ["transplant", "genetic molecular"],
    "Analyte(s)": ["gene expression profile of RNA"],
    "Specimen Type(s)": ["Peripheral blood mononuclear cells"],
    "Specimen Container(s)": ["BD Vacutainer CPTâ„¢ Cell Preparation tube with sodium citrate anticoagulant"],
    "Instrument(s)/Platform(s)": ["Roche LightCycler 480 II (LC480) thermal cyclers"],
    "Method(s)/Technology(ies)": ["qRT-PCR", "Gene expression analysis"],
    "Methodologies": ["Gene expression profiling", "RT-PCR", "Molecular expression testing"],
    "Submission Type(s)": ["Test", "Assay"],
    "Document Summary": "FDA 510(k) summary for CareDx AlloMap Heart Molecular Expression Testing using qRT-PCR to monitor heart transplant rejection risk",
    "Indications for Use Summary": "Aids in identifying heart transplant recipients (15+ years, 2+ months post-transplant) with stable allograft function who have low probability of moderate/severe acute cellular rejection, used in conjunction with standard clinical assessment."
}